Expression patterns of α2,3-Sialyltransferase I and α2,6-Sialyltransferase I in human cutaneous epithelial lesions

European Journal of Histochemistry

Volumn 57, Issue 1, 2013, Pages 41-45

  Ferreira, Steffany A ^a   Vasconcelos, J L A ^a   Cavalcanti, C L B ^a   Silva, R C W C ^a   Bezerra, C L ^a   Rego M J B M ^a   Beltrao E I C ^a,b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b DEPARTAMENTO DE MICOLOGIA   (Brazil)

Author keywords

Actinic keratosis; Basal cell carcinoma; Keratoacanthoma; Sialic acid; Squamous cell carcinoma; 2,3 sialyltransferases; 2,6 sialyltransferases

Indexed keywords

EID: 84874391236     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/ejh.2013.e7     Document Type: Article

References (37)

1. Lee JH, Peyson JK, Kim DW, Lee SH, Nam HS, Kim CH, et al. Elevated c-Src and c-Yes expression in malignant skin cancers. J Exp Clin Cancer Res 2010;29:116.
2. Martinez MAR, Francisco G, Cabral LS, Ruiz IRG, Festa Neto C. Genética molecular aplicada ao câncer cutâneo não melanoma. Anais Brasileiros de Dermatologia 2006;81:405-19.
3. Ghazarian H, Idoni B, Oppenheimer SB. A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem 2011;113:236-47.
4. Taniguchi N, Korekane H. Branched N-glycans and their implications for cell adhesion, signaling and clinical applications for cancer biomarkers and in therapeutics. BMB Rep 2011;44:772-81.
5. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-42.
6. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 2006;7: 599-604.
7. Brockhausen I. Biosynthesis of complex Mucin-Type O-Glycans. (editors) Lew M, Hung-Wen L, Comprehensive natural products II. Oxford: Elsevier; 2010, p. 315-50.
8. Paulson JC, Blixt O, Collins BE. Sweet spots in functional glycomics. Nat Chem Biol 2006;2:238-48.
9. Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S, et al. Overexpression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology 2010;20): 1241-50.
10. Cazet A, Julien S, Bobowski M, Krzewinski-Recchi MA, Harduin-Lepers A, Groux-Degroote S, et al. Consequences of the expression of sialylated antigens in breast cancer. Carbohydr Res 2010;345: 1377-83.
11. Harduin-Lepers A, Krzewinski-Recchi MA, Colomb F, Foulquier F, Groux-Degroote S, Delannoy P. Sialyltransferases functions in cancers. Front Biosci 2012;4:499-515.
12. Drinnan NB, Halliday J, Ramsdale T. Inhibitors of sialyltransferases: potential roles in tumor growth and metastasis. Mini Rev Med Chem 2003;3:501-17.
13. Hennet T, Chui D, Paulson JC, Marth JD. Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci USA 1998;95:4504-9.
14. Senda M, Ito A, Tsuchida A, Hagiwara T, Kaneda T, Nakamura Y, et al. Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: downregulation of ST6GalNAc VI in renal cancers. Biochem J 2007;402:459-70.
15. Varki A, Cummings RD, Esko JD. Essentials of glycobiology, 2nd ed. Cold Spring Harbor, NY, 2009.
16. Li YL, Wu GZ, Zeng L, Dawe GS, Sun L, Loers G, et al. Cell surface sialylation and fucosylation are regulated by the cell recognition molecule L1 via PLCgamma and cooperate to modulate embryonic stem cell survival and proliferation. FEBS Lett 2009;583:703-10.
17. Dornelas MT, Rodrigues MF, Machado DC, Gollner AM, Ferreira AP. [Expression of cell proliferation and apoptosis biomarkers in skin spinocellular carcinoma and actinic keratosis]. [Article in Portuguese]. An Bras Dermatol 2009;84:469-75.
18. Melo-Júnior MR, Araújo-Filho JLS, Patu VJRM, Machado MCFdP, Beltrão EIC, Carvalho Jr. LB. Digital image analysis of skin neoplasms evaluated by lectin histochemistry: potential marker to biochemical alterations and tumour differential diagnosis. J Bras Patol Med Lab 2006;42: 455-60.
19. Smetana K, Jr., Plzak J, Dvorankova B, Holikova Z. Functional consequences of the glycophenotype of squamous epitheliapractical employment. Folia Biol 2003;49: 118-27.
20. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 2009;19:507-14.
21. Tsukamoto H, Takakura Y, Yamamoto T. Purification, cloning, and expression of an alpha/beta-galactoside alpha-2,3-sialyltransferase from a luminous marine bacterium, Photobacterium phosphoreum. J Biol Chem 2007;282:29794-802.
22. Wang PH. Altered glycosylation in cancer: sialic acids and sialyltransferases. J Cancer Mol 2005;1:73-81.
23. Huang S, Day TW, Choi MR, Safa AR. Human beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxolinduced apoptosis in ovarian cancer cells by downregulating caspase-8 activity. Mol Cell Biochem 2009;331:81-8.
24. Taatjes D, Roth J, Weinstein J, Paulson J. Post-Golgi apparatus localization and regional expression of rat intestinal sialyltransferase detected by immunoelectron microscopy with polypeptide epitope-purified antibody. J Biol Chem 1988;263:6302-9.
25. Burger PC, Lotscher M, Streiff M, Kleene R, Kaissling B, Berger EG. Immunocytochemical localization of alpha2,3(N)-sialyltransferase (ST3Gal III) in cell lines and rat kidney tissue sections: evidence for golgi and post-golgi localization. Glycobiology 1998;8:245-57.
26. Videira PA, Correia M, Malagolini N, Crespo HJ, Ligeiro D, Calais FM, et al. ST3Gal. I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer 2009;9:357.
27. Dall'Olio F, Chiricolo M. Sialyltransferases in cancer. Glycoconj J 2001;18:841-50.
28. Cao Y, Merling A, Crocker PR, Keller R, Schwartz-Albiez R. Differential expression of beta-galactoside alpha2,6 sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma. Lab Invest 2002;82:1515-24.
29. Poon TC, Chiu CH, Lai PB, Mok TS, Zee B, Chan AT, et al. Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma. World J Gastroenterol 2005;11: 6701-6.
30. Ismail F, Ikram M, Purdie K, Harwood C, Leigh I, Storey A. Cutaneous squamous cell carcinoma (SCC) and the DNA damage response: pATM expression patterns in pre-malignant and malignant keratinocyte skin lesions. PLoS One 2011; 6:e21271.
31. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005;26:1657-67.
32. Krunic AL, Garrod DR, Madani S, Buchanan MD, Clark RE. Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasms with squamous phenotype: actinic keratosis, keratoacanthoma and squamous cell carcinoma of the skin. Br J Cancer 1998;77:1275-9.
33. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 1993;15:332-42.
34. Mandrell JC, Santa Cruz D. Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma? Semin Diagn Pathol 2009;26:150-63.
35. Pilloni L, Bianco P, Manieli C, Senes G, Coni P, Atzor L, et al. Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas. Eur J Histochem 2009;53:113-6.
36. Chen JY, Tang YA, Huang SM, Juan HF, Wu LW, Sun YC, et al. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res 2011;71:473-83.
37. Christie DR, Shaikh FM, Lucas JAt, Lucas JA, 3rd, Bellis SL. ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res 2008;1:3.